UK Regulator Issues 41 ‘Innovation Passports’ In First Year Of New Pathway
Oncology, Neurology And Respiratory Drugs Dominate
The UK’s ILAP, a post-Brexit scheme introduced in 2021 to accelerate the development of, and access to, new innovative medicines, proved popular in its first year of operation. A total of 71 applications were received last year from companies wanting to take advantage of the regulatory advice, tools and flexibilities on offer.
